Extrauterine pelvic serous carcinomas

Current update on pathology and cross-sectional imaging findings

Venkata Katabathina, Farhan S. Amanullah, Christine O. Menias, Melissa M. Chen, Philip T Valente, Kedar N Chintapalli, Srinivasa R. Prasad

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The spectrum of extrauterine pelvic serous carcinomas includes ovarian serous carcinoma, primary peritoneal serous carcinoma, and primary fallopian tube carcinoma. Ovarian serous carcinoma, the most common ovarian malignant epithelial neoplasm, consists of two distinct entities: high-grade and low-grade serous carcinomas. Primary peritoneal serous carcinoma and primary fallopian tube carcinoma are rare malignancies that share many characteristics of high-grade serous carcinomas. Recent advances in the genetics and molecular biology of gynecologic cancers have suggested a common origin of many extrauterine pelvic serous carcinomas from fallopian tube epithelium.With the exception of low-grade serous carcinomas, which arise from cortical inclusion cysts lined by tubal epithelium, most extrauterine pelvic serous carcinomas are believed to originate from serous tubal intraepithelial carcinomas and show similar clinical-biologic behaviors and natural histories. Indeed, the International Federation of Gynecology and Obstetrics Committee on Gynecologic Oncology recently recognized that these cancers should be considered collectively, with a common system of staging and management strategies for ovarian, primary peritoneal, and fallopian tube cancers. A paradigm shift has occurred in our understanding of the pathogenesis of extrauterine pelvic serous carcinomas that has the potential to change current strategies for screening, prevention, diagnosis, and management. Ultrasonography (US), computed tomography (CT), magnetic resonance imaging, and combined positron emission tomography and CT are pivotal in screening, initial diagnosis, and treatment follow-up; however, because of this paradigm shift, new radiologic techniques, such as contrast material-enhanced US and molecular US imaging, and various optical imaging techniques are being investigated as important screening and diagnostic tools. Because of evolving knowledge of genetic and molecular changes underlying the pathogenesis of extrauterine pelvic serous carcinomas, new targeted therapies are being developed to improve patient prognosis.

Original languageEnglish (US)
Pages (from-to)918-932
Number of pages15
JournalRadiographics
Volume36
Issue number3
DOIs
StatePublished - May 1 2016

Fingerprint

Pathology
Carcinoma
Fallopian Tubes
Ultrasonography
Molecular Biology
Fallopian Tube Neoplasms
Epithelium
Neoplasms
Molecular Imaging
Optical Imaging
Carcinoma in Situ
Biological Products
Natural History
Gynecology
Contrast Media
Obstetrics
Cysts
Tomography
Magnetic Resonance Imaging
Therapeutics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Katabathina, V., Amanullah, F. S., Menias, C. O., Chen, M. M., Valente, P. T., Chintapalli, K. N., & Prasad, S. R. (2016). Extrauterine pelvic serous carcinomas: Current update on pathology and cross-sectional imaging findings. Radiographics, 36(3), 918-932. https://doi.org/10.1148/rg.2016150130

Extrauterine pelvic serous carcinomas : Current update on pathology and cross-sectional imaging findings. / Katabathina, Venkata; Amanullah, Farhan S.; Menias, Christine O.; Chen, Melissa M.; Valente, Philip T; Chintapalli, Kedar N; Prasad, Srinivasa R.

In: Radiographics, Vol. 36, No. 3, 01.05.2016, p. 918-932.

Research output: Contribution to journalArticle

Katabathina, V, Amanullah, FS, Menias, CO, Chen, MM, Valente, PT, Chintapalli, KN & Prasad, SR 2016, 'Extrauterine pelvic serous carcinomas: Current update on pathology and cross-sectional imaging findings', Radiographics, vol. 36, no. 3, pp. 918-932. https://doi.org/10.1148/rg.2016150130
Katabathina, Venkata ; Amanullah, Farhan S. ; Menias, Christine O. ; Chen, Melissa M. ; Valente, Philip T ; Chintapalli, Kedar N ; Prasad, Srinivasa R. / Extrauterine pelvic serous carcinomas : Current update on pathology and cross-sectional imaging findings. In: Radiographics. 2016 ; Vol. 36, No. 3. pp. 918-932.
@article{e43a6b2d8b98450f822c7879b760feb7,
title = "Extrauterine pelvic serous carcinomas: Current update on pathology and cross-sectional imaging findings",
abstract = "The spectrum of extrauterine pelvic serous carcinomas includes ovarian serous carcinoma, primary peritoneal serous carcinoma, and primary fallopian tube carcinoma. Ovarian serous carcinoma, the most common ovarian malignant epithelial neoplasm, consists of two distinct entities: high-grade and low-grade serous carcinomas. Primary peritoneal serous carcinoma and primary fallopian tube carcinoma are rare malignancies that share many characteristics of high-grade serous carcinomas. Recent advances in the genetics and molecular biology of gynecologic cancers have suggested a common origin of many extrauterine pelvic serous carcinomas from fallopian tube epithelium.With the exception of low-grade serous carcinomas, which arise from cortical inclusion cysts lined by tubal epithelium, most extrauterine pelvic serous carcinomas are believed to originate from serous tubal intraepithelial carcinomas and show similar clinical-biologic behaviors and natural histories. Indeed, the International Federation of Gynecology and Obstetrics Committee on Gynecologic Oncology recently recognized that these cancers should be considered collectively, with a common system of staging and management strategies for ovarian, primary peritoneal, and fallopian tube cancers. A paradigm shift has occurred in our understanding of the pathogenesis of extrauterine pelvic serous carcinomas that has the potential to change current strategies for screening, prevention, diagnosis, and management. Ultrasonography (US), computed tomography (CT), magnetic resonance imaging, and combined positron emission tomography and CT are pivotal in screening, initial diagnosis, and treatment follow-up; however, because of this paradigm shift, new radiologic techniques, such as contrast material-enhanced US and molecular US imaging, and various optical imaging techniques are being investigated as important screening and diagnostic tools. Because of evolving knowledge of genetic and molecular changes underlying the pathogenesis of extrauterine pelvic serous carcinomas, new targeted therapies are being developed to improve patient prognosis.",
author = "Venkata Katabathina and Amanullah, {Farhan S.} and Menias, {Christine O.} and Chen, {Melissa M.} and Valente, {Philip T} and Chintapalli, {Kedar N} and Prasad, {Srinivasa R.}",
year = "2016",
month = "5",
day = "1",
doi = "10.1148/rg.2016150130",
language = "English (US)",
volume = "36",
pages = "918--932",
journal = "Radiographics",
issn = "0271-5333",
publisher = "Radiological Society of North America Inc.",
number = "3",

}

TY - JOUR

T1 - Extrauterine pelvic serous carcinomas

T2 - Current update on pathology and cross-sectional imaging findings

AU - Katabathina, Venkata

AU - Amanullah, Farhan S.

AU - Menias, Christine O.

AU - Chen, Melissa M.

AU - Valente, Philip T

AU - Chintapalli, Kedar N

AU - Prasad, Srinivasa R.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - The spectrum of extrauterine pelvic serous carcinomas includes ovarian serous carcinoma, primary peritoneal serous carcinoma, and primary fallopian tube carcinoma. Ovarian serous carcinoma, the most common ovarian malignant epithelial neoplasm, consists of two distinct entities: high-grade and low-grade serous carcinomas. Primary peritoneal serous carcinoma and primary fallopian tube carcinoma are rare malignancies that share many characteristics of high-grade serous carcinomas. Recent advances in the genetics and molecular biology of gynecologic cancers have suggested a common origin of many extrauterine pelvic serous carcinomas from fallopian tube epithelium.With the exception of low-grade serous carcinomas, which arise from cortical inclusion cysts lined by tubal epithelium, most extrauterine pelvic serous carcinomas are believed to originate from serous tubal intraepithelial carcinomas and show similar clinical-biologic behaviors and natural histories. Indeed, the International Federation of Gynecology and Obstetrics Committee on Gynecologic Oncology recently recognized that these cancers should be considered collectively, with a common system of staging and management strategies for ovarian, primary peritoneal, and fallopian tube cancers. A paradigm shift has occurred in our understanding of the pathogenesis of extrauterine pelvic serous carcinomas that has the potential to change current strategies for screening, prevention, diagnosis, and management. Ultrasonography (US), computed tomography (CT), magnetic resonance imaging, and combined positron emission tomography and CT are pivotal in screening, initial diagnosis, and treatment follow-up; however, because of this paradigm shift, new radiologic techniques, such as contrast material-enhanced US and molecular US imaging, and various optical imaging techniques are being investigated as important screening and diagnostic tools. Because of evolving knowledge of genetic and molecular changes underlying the pathogenesis of extrauterine pelvic serous carcinomas, new targeted therapies are being developed to improve patient prognosis.

AB - The spectrum of extrauterine pelvic serous carcinomas includes ovarian serous carcinoma, primary peritoneal serous carcinoma, and primary fallopian tube carcinoma. Ovarian serous carcinoma, the most common ovarian malignant epithelial neoplasm, consists of two distinct entities: high-grade and low-grade serous carcinomas. Primary peritoneal serous carcinoma and primary fallopian tube carcinoma are rare malignancies that share many characteristics of high-grade serous carcinomas. Recent advances in the genetics and molecular biology of gynecologic cancers have suggested a common origin of many extrauterine pelvic serous carcinomas from fallopian tube epithelium.With the exception of low-grade serous carcinomas, which arise from cortical inclusion cysts lined by tubal epithelium, most extrauterine pelvic serous carcinomas are believed to originate from serous tubal intraepithelial carcinomas and show similar clinical-biologic behaviors and natural histories. Indeed, the International Federation of Gynecology and Obstetrics Committee on Gynecologic Oncology recently recognized that these cancers should be considered collectively, with a common system of staging and management strategies for ovarian, primary peritoneal, and fallopian tube cancers. A paradigm shift has occurred in our understanding of the pathogenesis of extrauterine pelvic serous carcinomas that has the potential to change current strategies for screening, prevention, diagnosis, and management. Ultrasonography (US), computed tomography (CT), magnetic resonance imaging, and combined positron emission tomography and CT are pivotal in screening, initial diagnosis, and treatment follow-up; however, because of this paradigm shift, new radiologic techniques, such as contrast material-enhanced US and molecular US imaging, and various optical imaging techniques are being investigated as important screening and diagnostic tools. Because of evolving knowledge of genetic and molecular changes underlying the pathogenesis of extrauterine pelvic serous carcinomas, new targeted therapies are being developed to improve patient prognosis.

UR - http://www.scopus.com/inward/record.url?scp=84966577751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966577751&partnerID=8YFLogxK

U2 - 10.1148/rg.2016150130

DO - 10.1148/rg.2016150130

M3 - Article

VL - 36

SP - 918

EP - 932

JO - Radiographics

JF - Radiographics

SN - 0271-5333

IS - 3

ER -